The volume for IMTX increased for one day, resulting in a record-breaking daily growth of 235%
Immatics is a biotechnology company that is involved in the development of immunotherapies for cancer treatment. Recently, the company's stock experienced a significant increase in trading volume, resulting in a record-breaking daily growth of 235% of the 65-Day Volume Moving Average. As finance analytics, it is important to analyze this trend and understand the factors driving it.
The 65-Day Volume Moving Average is a technical analysis indicator that is used to measure the average trading volume of a stock over the past 65 days. When the volume for a stock exceeds this average, it is considered a signal of increased interest in the stock by investors.
The surge in trading volume for Immatics can be attributed to several factors, including positive developments in the company's pipeline and increased investor optimism in the biotech industry as a whole. Immatics has recently reported positive results from its clinical trials for its cancer immunotherapy treatments, which has generated significant interest among investors.
Moreover, the biotech industry has been gaining momentum recently, with several companies making breakthroughs in the development of new treatments and vaccines. This has attracted investor attention, resulting in increased trading activity for many biotech stocks, including Immatics.
The significant increase in trading volume for Immatics indicates that the stock is attracting a lot of attention from investors. However, it is important to note that such rapid growth is not sustainable over the long term and often leads to price corrections in the future. As such, investors should exercise caution and conduct thorough research before investing in Immatics or any other stock experiencing a similar trend.
Momentum Indicator for IMTX turns negative, indicating new downward trend
IMTX saw its Momentum Indicator move below the 0 level on August 06, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned negative. In of the 86 cases, the stock moved further down in the following days. The odds of a decline are at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for IMTX turned negative on August 06, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .
IMTX moved below its 50-day moving average on August 19, 2025 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for IMTX crossed bearishly below the 50-day moving average on August 22, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for IMTX entered a downward trend on August 29, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for IMTX's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 50-day moving average for IMTX moved above the 200-day moving average on August 11, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IMTX advanced for three days, in of 286 cases, the price rose further within the following month. The odds of a continued upward trend are .
IMTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.144) is normal, around the industry mean (19.615). P/E Ratio (27.608) is within average values for comparable stocks, (52.235). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.663). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (3.932) is also within normal values, averaging (303.992).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. IMTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer
Industry Biotechnology
Advertisement